CV - SIES

GALIMBERTI SARA
CURRICULUM VITAE
INFORMAZIONI PERSONALI
Nata a La Spezia, il 08/08/1967
Coniugata con 3 figli
Residente in San Giuliano Terme (PI)
e.mail: [email protected]
tel. 050992755 – 050993486
SETTORE PROFESSIONALE E POSIZIONE ATTUALE
M.D., Ph.D – Ricercatore confermato Università di Pisa – MED015
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia
CURRICULUM UNIVERSITARIO
Settembre 1986: Vincitrice concorso per posto di allievo Scuola Superiore di Studi
Universitari e di Perfezionamento S. Anna – Pisa;
06/10/1992: laurea in Medicina e Chirurgia con tesi sperimentale sulla
chemioresistenza e leucosi acute – Votazione: 110/100 L + dignità di stampa;
18/12/1992 – 17/12/1995: allieva del corso di Perfezionamento della Classe di
Scienze Sperimentali -Settore di Medicina e Chirurgia – presso la Scuola Superiore di
Studi Universitari e di Perfezionamento S. Anna – Pisa;
21/01/1997: conseguimento Diploma di Perfezionamento, equipollente al Dottorato di
Ricerca come previsto dall'art. 2 – punto 3- legge 14/02/1987, n 41 della istituzione
della Scuola Superiore di Studi Universitari e di Perfezionamento S. Anna – Pisa –
Votazione: 50/50 L
30/10/1996 – 22/10/1999: allieva Scuola di Specializzazione in Ematologia Università
di Pisa
22/10/1999: diploma di Specialista in Ematologia - Votazione: 50/50 L
INCARICHI PROFESSIONALI
28/07/2000 – 28/11/2000: contratto di prestazione d'opera intellettuale con il
Dipartimento di Scienze dell'Uomo e dell'Ambiente – Prof. Roberto Barale – per analisi
molecolare di geni coinvolti nella chemioresistenza;
29/11/2000-01/06/2001: contratto come Dirigente Medico I Livello presso L'Azienda
Ospedaliera Pisana – U.O. Ematologia Pisa;
01/06/2001: nomina a Ricercatore Universitario MED/15 presso il Dipartimento di
Oncologia, Trapianti, Nuove Tecnologie in Medicina – Università di Pisa.
ESPERIENZA PROFESSIONALE
Già durante il periodo del corso di Perfezionamento la Dr. Galimberti ha frequentato
continuativamente il laboratorio molecolare ed il reparto della U.O. Ematologia
dell’Università di Pisa, diretto dal Prof. Mario Petrini.
Dal Novembre al Dicembre 1993 e successivamente nel Febbraio 2005 la Dr.
Galimberti ha frequentato il laboratorio del Prof. Giuseppe Saglio (Orbassano, Torino)
dove si stavano mettendo a punto le prime tecniche diagnostiche molecolari qualitative
e successivamente quantitative fondamentali nell'iter diagnostico della leucemia
mieloide acuta e cronica.
Da allora l'attivita’ di ricerca si è sempre rivolta principalmente ad aspetti bio-molecolari
sottostanti la patogenesi delle principali malattie ematologiche.
In particolare, oggetto di studio sono stati: i meccanismi responsabili della
chemioresistenza, ricerca di marcatori prognostici in ambito molecolare e di geni
candidabili per il monitoraggio del paziente affetto da malattie ematologiche, anche nel
post-trapianto.
Particolare interesse è stato altresì rivolto allo studio di meccanismi di trasduzione del
segnale di nuovi farmaci, quali inibitori dei proteasomi ed inibitori delle istone
deacetilasi.
La Dr. Galimberti è responsabile scientifico del Laboratorio di Biologia Molecolare della
U.O. di Ematologia, riferimento regionale per l'Area Vasta Pisana e riferimento dal
2005 al 2011 del Gruppo Italiano per lo Studio dei Linfomi (GISL).
Dal 2010 tale laboratorio è uno dei 4 laboratori italiani di riferimento per la Federazione
Italiana Linfomi (FIL), impegnati nella standardizzazione delle metodiche molecolari per
la valutazione della malattia minima residua nei pazienti affetti da linfoma.
E’ stata altresì responsabile di trials clinici di fase III nelle leucosi acute e nella
leucemia mieloide cronica, anche nel contesto del gruppo cooperatore italiano
GIMEMA.
Il laboratorio molecolare in cui la Dr. Galimberti opera è con altri 54 laboratori italiani
parte del network italiano per la diagnostica ed il follow-up dei pazienti con leucemia
mieloide cronica LabNet.
Attualmente responsabile della stesura “linee guida” per l’Area Vasta Nord-Ovest e dei
protocolli clinici per la leucemia mieloide cronica della UO Ematologia
STAGES NAZIONALI ED INTERNAZIONALI
Laboratorio Prof. Saglio, Orbassano (TO) 1993, 2004
Laboratorio Citogenetica e Biologia Molecolare Dr. Knuutila, Helsinki, Finland, 2001
Laboratorio Citogenetica e Biologia Molecolare Prof. Nagy, Budapest, Hungary, 2003,
2008
Laboratorio e Clinica Ematologia Karolinska, Stochkolm, Sweden, Prof. HellstromLindberg, Prof. Hassan, 2007, 2011
MDACC Houston, USA, 2009
Cancer Center Tampa, USA, 2011
COLLABORAZIONI
NAZIONALI
Ematologie di Modena, Reggio Calabria, Ancona, Cosenza, Catania, Roma, Perugia,
Foggia, Torino, Pesaro, Bologna, Rionero in Vulture, Firenze, Siena.
INTERNAZIONALI
Laboratorio di Citogenetica dell’Università di Sammelweis (Budapest, Ungheria),
laboratorio biologia molecolare dell’Univeristà di Kokaeli, Turchia, Karolinska Institutet
di Stoccolma, Svezia, NIH (Bethesda, USA), BC Cancer Research Centre,Vancouver,
BC, Canada
ATTIVITA' DIDATTICA
1-insegnamento di ADO chemioresistenza nei Disordini Ematologici per Corso di
Laurea in Tecniche Di Laboratorio Biomedico – A.A. 2003-2004, 2005-2006, 20062007, 2007-2008, 2008-2009, 2009-2010
2- insegnamento di Malattie del Sangue - Modulo dell'insegnamento Malattie del
Sangue e dell'Apparato Respiratorio. Farmacologia per Corso di Laurea in Dietistica –
A.A. 2003-2004, 2005-2006, 2006-2007, 2207-2008, 2008-2009, 2009-2010, 20102011
3- insegnamento di Tipizzazione Leucocitaria - Modulo dell'insegnamento Tecniche
Diagnostiche di Patologia Clinica ed Immunoematologia per Corso di Laurea in
Tecniche di laboratorio Biomedico A.A. 2003-2004, 2005-2006, 2006-2007, 2007-2008,
2008-2009, 2009-2010, 2010-2011, 2011-2012, 2012-2013
4- Scuola di Specializzazione in ematologia – A.A. 2007-2008, 2008-2009, 2009-2010,
2010-2011, 2011-2012, 2012-2013, 2013-2014
5- Dottorato in Genetica e Microbiologia – A.A. 2006-2007, 2007-2008, 2008-2009
6- Dottorato in Neuroscienze e Scienze endocrino-metaboliche – A.A. 2010-2011
7- Dottorato in Scienze Biologiche e Molecolari – A.A. 2010-2011
8- Dottorato in Genetica, Oncologia e Medicina Clinica – GenOMec – Regione
Toscana – Università di Siena - 2012-2013, 2013-2014
COMPETENZE PERSONALI
La Dr. Galimberti ha partecipato a molti congressi nazionali ed internazionali, spesso
come relatrice, ed alla organizzazione dei congressi e corsi residenziali tenutisi sotto
l'egida della UO Ematologia di Pisa. E' stata più volte chiamata alla revisione di lavori
internazionali.
Buona conoscenza della lingua inglese e francese.
Buona conoscenza in ambito statistico (SPSS).
PUBBLICAZIONI
Numero di pubblicazioni in “extenso”: 154; H-index: 19.
2014
Carulli G, Baratè C, Marini A, Ottaviano V, Cervetti G, Fontanelli G, Guerrini F, Arici R,
Guerri V, Di Paolo A, Polillo M, Ferreri MI, Galimberti S, Petrini M. Hematol Oncol. 2014 Sep 25.
Focosi, D., Macera, L., Ciabatti, E., Galimberti, S., Petrini, M., Carella, A.M., Pistello, M.,
Ceccherini-Nelli, L., Maggi, F. No reactivation of JCV in bone marrow of follicular lymphoma
patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan. (2014) Infection, . Article
in Press.
Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B,
Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, Piccaluga
PP; on behalf of Fondazione Italiana Linfomi - MrdNetwork. Comparison of different DNA
extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi MRD Network. Leuk Lymphoma. 2014 Aug 12:1-23
Ibatici, A., Pica, G.M., Nati, S., Vitolo, U., Botto, B., Ciochetto, C., Petrini, M., Galimberti, S.,
Ciabatti, E., Orciuolo, E., Zinzani, P.L., Cascavilla, N., Guolo, F., Fraternali Orcioni, G., Carella,
A.M. Safety and efficacy of 90Yttrium-Ibritumomab-Tiuxetan for untreated follicular lymphoma
patients. An Italian cooperative study (2014) British Journal of Haematology, 164 (5), pp. 710716.
Matteuzzi, B., Pieri, L., Lisi, F., Galimberti, S., Campani, D., Colagrande, S. Imaging studies in
extramedullary hematopoiesis of the spleen (2014) Annals of Hematology, 93 (2), pp. 347-349.
Fontanelli, G., Rocco, M., Caracciolo, F., Benedetti, E., Buda, G., Orciuolo, E., Carulli, G.,
Galimberti, S., Azzarà, A., Petrini, M. Sorafenib as monotherapy or in association with
cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced
acute myeloid leukemia (2014) Clinical Lymphoma, Myeloma and Leukemia, 14 (1), pp. e13e17.
Di Paolo, A., Polillo, M., Capecchi, M., Cervetti, G., Baratè, C., Angelini, S., Guerrini, F.,
Fontanelli, G., Arici, R., Ciabatti, E., Grassi, S., Bocci, G., Hrelia, P., Danesi, R., Petrini, M.,
Galimberti, S. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients
affected by chronic myeloid leukemia (2014) Pharmacogenomics Journal, 14 (4), pp. 328-335.
2013
Offidani, M., Corvatta, L., Maracci, L., Liberati, Am., Ballanti, S., Attolico, I., Caraffa, P.,
Alesiani, F., Di Toritto, T.C., Gentili, S., Tosi, P., Brunori, M., Derudas, D., Ledda, A., Gozzetti,
A., Cellini, C., Malerba, L., Mele, A., Andriani, A., Galimberti, S., Mondello, P., Pulini, S.,
Coppetelli, U., Fraticelli, P., Olivieri, A., Leoni, P. Efficacy and tolerability of bendamustine,
bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase
II study (2013) Blood Cancer Journal, 3 (11), art. no. e162,
Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Ceccarelli, M., Boccomini, C., Genuardi, E.,
Chiappella, A., Baldini, L., Rossi, G., Pulsoni, A., Di Raimondo, F., Rigacci, L., Pinto, A.,
Galimberti, S., Bari, A., Rota-Scalabrini, D., Ferrari, A., Zaja, F., Gallamini, A., Specchia, G.,
Musto, P., Rossi, F.G., Gamba, E., Evangelista, A., Vitolo, U. Persistence of minimal residual
disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximabintensive program (2013) Blood, 122 (23), pp. 3759-3766.
Della Starza, I., Cavalli, M., Del Giudice, I., Barbero, D., Mantoan, B., Genuardi, E., Urbano,
M., Mannu, C., Gazzola, A., Ciabatti, E., Guarini, A., Foà, R., Galimberti, S., Piccaluga, P.,
Gaidano, G., Ladetto, M., Monitillo, L. Comparison of two real-time quantitative polymerase
chain reaction strategies for minimal residual disease evaluation in lymphoproliferative
disorders: Correlation between immunoglobulin gene mutation load and real-time quantitative
polymerase chain reaction performance (2013) Hematological Oncology, . Article in Press.
Benedetti, E., Bruno, B., McDonald, G.B., Paolicchi, A., Caracciolo, F., Papineschi, F., Pelosini,
M., Campani, D., Galimberti, S., Petrini, M. Prospective qualitative and quantitative noninvasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography
(2013) Bone Marrow Transplantation, 48 (11), pp. 1421-1428.
Oliva, E.N., Latagliata, R., Laganà, C., Breccia, M., Galimberti, S., Morabito, F., Poloni, A.,
Balleari, E., Cortelezzi, A., Palumbo, G., Sanpaolo, G., Volpe, A., Specchia, G., Finelli, C.,
D'Errigo, M.G., Rodà, F., Alati, C., Alimena, G., Nobile, F., Aloe Spiriti, M.A. Lenalidomide in
International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic
syndromes with del(5q): An Italian phase II trial of health-related quality of life, safety and
efficacy (2013) Leukemia and Lymphoma, 54 (11), pp. 2458-2465.
Cervetti, G., Galimberti, S., Pelosini, M., Ghio, F., Cecconi, N., Petrini, M. Significant efficacy of
2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma
(SMZL): Extended follow-up (2013) Annals of Oncology, 24 (9), art. no. mdt181, pp. 24342438.
Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Raimondo, F.D., Carella,
A.M., Pulsoni, A., Merli, F., Arcaini, L., Angrilli, F., Stelitano, C., Gaidano, G., Dell'Olio, M.,
Marcheselli, L., Franco, V., Galimberti, S., Sacchi, S., Brugiatelli, M. R-CVP versus R-CHOP
versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma:
Results of the FOLL05 trial conducted by the fondazione italiana linfomi (2013) Journal of
Clinical Oncology, 31 (12), pp. 1506-1513.
Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F,
Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A,
Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R. (2013). Biological activity of
lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling
from a multicenter phase II study. ANNALS OF HEMATOLOGY (2013) vol. 92, p. 25-32,
ISSN: 0939-5555
Buda G, Orciuolo E, Carulli G, Galimberti S, Ghio F, Cervetti G, Pelosini M, Petrini M.
(2013). Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus
doxorubicin and dexamethasone as induction therapy in previously untreated multiple
myeloma patients. . ACTA HAEMATOLOGICA, vol. 129, 2013, p. 35-39, ISSN: 0001-5792
Oliva EN, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari
E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D'Errigo MG,
Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA. (2013). Lenalidomide in International
Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with
del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. .
LEUKEMIA & LYMPHOMA, 2013, vol. march 27, ISSN: 1042-8194
2012
Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini
M, Levis A (2012). Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes
in patients with myelodysplastic syndromes: an ex-vivo study. . JOURNAL OF CLINICAL
HEMATOLOGY AND ONCOLOGY, 2012 vol. 5, ISSN: 0162-9360
Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F,
Di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M.
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the
initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo
Italiano Studio Linfomi. Br J Haematol. 2012 Feb;156(3):346-53
2011
Carulli G, Marini A, Ciancia EM, Bruno J, Vignati S, Lambelet P, Cannizzo E, Ottaviano V,
Galimberti S, Caracciolo F, Ferreri MI, Ciabatti E, Petrini M. Discordant lymphoma
consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the
bone marrow and peripheral blood: a case report. J Med Case Rep. 2011 Sep 23;5:476
Cannizzo E, Carulli G, Del Vecchio L, Azzarà A, Galimberti S, Ottaviano V, Preffer F,
Petrini M. Prethymic cytoplasmic CD3 negative acute lymphoblastic leukemia or acute
undifferentiated leukemia: a case report. Case Rep Hematol. 2011;2011:230568. doi:
10.1155/2011/230568. Epub 2011 Jul 28
Buda G, Orciuolo E, Galimberti S, Pelosini M, Petrini M. Pegylated liposomal doxorubicin in
combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple
myeloma pretreated patients. Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277010-1136-5. Epub 2010 Dec 22.
Galimberti S, Nagy B, Ciancia E, Caracciolo F, Benedetti E, Pelosini M, Focosi D, Petrini
M. Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial
growth factor polymorphisms. Leuk Lymphoma. 2011 Jan;52(1):142-4.
1
2010
4
1
2010
5
1
2010
6
1
2010
7
1
2010
8
1
2010
9
2
2010
0
Carulli G, Orciuolo E, Cannizzo E, Bianchi G, Giuntini S, Ottaviano V, Galimberti S,
Marini A, Buda G, Ghimenti M, Petrini M. (2010). Combination of morphology, flow
cytometry and PCR assay to detect bone marrow infiltration in B-cell non-Hodgkin's
lymphomas.. LA CLINICA TERAPEUTICA, vol. 161, p. 253-258, ISSN: 0009-9074
Orciuolo E, Buda G, Sordi E, Baraté C, Galimberti S, Ciancia E, Petrini M. (2010).
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. .
LEUKEMIA RESEARCH, vol. 34, p. 184-189, ISSN: 0145-2126
Carulli G, Cannizzo E, Ottaviano V, Cervetti G, Buda G, Galimberti S, Baratè C, Marini
A, Petrini M (2010). Abnormal phenotype of bone marrow plasma cells in patients with
chronic myeloid leukemia undergoing therapy with Imatinib. . LEUKEMIA RESEARCH,
vol. 34, p. 1336-1339, ISSN: 0145-2126
Buda G, Carulli G, Orciuolo E, Cannizzo E, Pelosini M, Galimberti S, Petrini M. (2010).
CD23 expression in plasma cell leukaemia.. BRITISH JOURNAL OF HAEMATOLOGY,
vol. 150, p. 724-725, ISSN: 0007-1048
Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F,
Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R,
Finelli C, Iacopino P, Alimena G, Latagliata R (2010). Changes in RPS14 expression
levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic
syndromes with chromosome 5q deletion. . EUROPEAN JOURNAL OF
HAEMATOLOGY, vol. 85, p. 231-235, ISSN: 0902-4441
Galimberti S, Canestraro M, Savli H, Palumbo GA, Tibullo D, Nagy B, Piaggi S,
Guerrini F, Cine N, Metelli MR, Petrini M. (2010). ITF2357 interferes with apoptosis and
inflammatory pathways in the HL-60 model: a gene expression study.. ANTICANCER
RESEARCH, vol. 30, p. 4525-4535, ISSN: 0250-7005
MORABITO F, GENTILE M, CIOLLI S, PETRUCCI MT, GALIMBERTI S, MELE G,
CASULLI AF, MANNINA D, PIRO E, PINOTTI G, PALMIERI S, CATALANO L,
CALLEA V, OFFIDANI M, MUSTO P, BRINGHEN S, BALDINI L, TOSI P, DI
RAIMONDO F, BOCCADORO M, PALUMBO A, CAVO M (2010). Safety and efficacy
of bortezomib-based regimens for multiple myeloma patients with renal impairment: a
retrospective study of Italian Myeloma Network GIMEMA. EUROPEAN JOURNAL OF
HAEMATOLOGY, vol. 84, p. 223-228, ISSN: 0902-4441
2
2010
1
2
2010
2
2
2010
3
2
2010
4
2
2010
5
2
2009
6
2
2009
7
2
2009
8
2
2009
9
3
2009
0
32009
Cervetti G, Galimberti S, Sordi E, Buda G, Orciuolo E, Cecconi N, Petrini M (2010).
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic
marginal zone lymphoma (SMZL). . ANNALS OF ONCOLOGY, vol. 21, p. 851-854,
ISSN: 0923-7534
Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, Guerrini F,
Piaggi S, Cine N, Metelli MR, Petrini M. (2010). Synergistic antiproliferative effect of
arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from
patients affected by myeloproliferative disorders. CANCER GENETICS AND
CYTOGENETICS, vol. 199, p. 110-120, ISSN: 0165-4608
Galimberti S, Petrini M. (2010). Temsirolimus in the treatment of relapsed and/or
refractory mantle cell lymphoma.. CANCER MANAGEMENT AND RESEARCH, vol. 2,
p. 181-189, ISSN: 1179-1322
GALIMBERTI S, NAGY B, PALUMBO GA, CIANCIA E, BUDA G, ORCIUOLO E,
MELOSI A, LAMBELET P, RONCA F, PETRINI M (2010). Vascular endothelial growth
factor polymorphisms in mantle cell lymphoma. ACTA HAEMATOLOGICA, vol. 123, p.
91-95, ISSN: 0001-5792
GALIMBERTI S, GHIO F, GUERRINI F, CIABATTI E, GRASSI S, FERRERI MI,
PETRINI M (2010). WT1 expression levels at diagnosis could predict long-term time-toprogression in adult patients affected by acute myeloid leukaemia and myelodysplastic
syndromes. BRITISH JOURNAL OF HAEMATOLOGY, vol. 149, p. 451-454, ISSN:
0007-1048
BUDA G, ORCIUOLO E, GALIMBERTI S, CECCONI N, PETRINI M (2009).
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best
possible response before autologous transplant for multiple myeloma. ACTA
HAEMATOLOGICA, vol. 122, p. 39-41, ISSN: 0001-5792
Benedetti E, proietti A, Miccoli P, Basolo F, Ciancia E, Erba PA, Galimberti S, Orsitto E,
Petrini M. (2009). Contrast-enhanced ultrasonography in nodular splenomegaly
associated with type B Niemann-Pick disease: an atypical hemangioma enhancement
pattern. JOURNAL OF ULTRASOUND, vol. 12, p. 85-92, ISSN: 1971-3495
FOCOSI D, KAST RE, METELLI MR, BENEDETTI E, GALIMBERTI S, PAPINESCHI F,
PETRINI M (2009). Enhancement of hematopoietic stem cell engraftment by inhibition
of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report
in a case of delayed graft failure. LEUKEMIA RESEARCH, vol. 33, p. 178-181, ISSN:
0145-2126
Focosi D, Sordi E, Papineschi F, Benedetti E, Galimberti S, Petrini M. (2009). Fatal
ongoing human cytomegalovirus reactivation during high-dose melphalan and
autologous stem cell transplantation. . JOURNAL OF MEDICAL VIROLOGY, vol. 81, p.
857-860, ISSN: 0146-6615
FOCOSI D, MAGGI F, PISTOLESI D, BENEDETTI E, PAPINESCHI F, GALIMBERTI
S, CECCHERINI-NELLI L, PETRINI M (2009). Hyperbaric oxygen therapy in BKVassociated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir:
case report and review of literature. LEUKEMIA RESEARCH, vol. 33, p. 556-560,
ISSN: 0145-2126
Focosi D, Pelosini M, Palla P, Galimberti S, Caracciolo F, Benedetti E, Papineschi F,
1
3
2009
2
3
2009
3
3
2009
4
Petrini M. (2009). Hypercytokinemia-induced metabolic encephalopathy in a multiple
myeloma patient on hemodialysis undergoing autologous stem cell transplantation:
clinical response after plasma exchange. . TRANSPLANT IMMUNOLOGY, vol. 21, p.
240-243, ISSN: 0966-3274
BUDA G, MARTINO A, MAGGINI V, ORCIUOLO E, GALIMBERTI S, GENTILE M,
MORABITO F, ANTOGNONI F, BRUNORI M, BARALE R, ROSSI AM, PETRINI M
(2009). MDR1 C3435T polymorphism indicates a different outcome in advanced
multiple myeloma. ACTA HAEMATOLOGICA, vol. 122, p. 42-45, ISSN: 0001-5792
PETRINI I, PACINI S, PETRINI M, FAZZI R, TROMBI L, GALIMBERTI S (2009).
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T
cells. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 39, p. 813-818,
ISSN: 0014-2972
GALIMBERTI S, FERRERI MI, SIMI P, AZZARÀ A, BARATÈ C, FAZZI R, CECCONI N,
CERVETTI G, GUERRINI F, PETRINI M (2009). Platelet-derived growth factor beta
receptor (PDGFRB) gene is rearranged in a significant percentage of myelodysplastic
syndromes with normal karyotype. BRITISH JOURNAL OF HAEMATOLOGY, vol. 147,
p. 763-766, ISSN: 0007-1048
allegati
3
2008
6
3
2008
7
Trombi L, Mattii L, Pacini S, D'Alessandro D, Battolla B, Orciuolo E, Buda G, Fazzi R,
Galimberti S, Petrini M. Source (2008). Human autologous plasma-derived clot as a
biological scaffold for mesenchymal stem cells in treatment of orthopedic healing..
JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 26, p. 176-183, ISSN: 0736-0266
Buda G, Orciuolo E, Maggini V, Galimberti S, Barale R, Rossi AM, Petrini M. Source
(2008). MDR1 pump: more than a drug transporter comment on "Regulatory
polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the
development of childhood acute lymphoblastic leukaemia" by Hattori et al. [Leuk. Res.
(in press)].. LEUKEMIA RESEARCH, vol. 32, p. 359-360, ISSN: 0145-2126
3
2008
8
Focosi D, Kast RE, Benedetti E, Papineschi F, Galimberti S, Petrini M. (2008).
Phenobarbital-associated bone marrow aplasia: a case report and review of the
literature.. ACTA HAEMATOLOGICA, vol. 119, p. 18-21, ISSN: 0001-5792
3
2008
9
FOCOSI D, CECCONI N, BONI G, ORCIUOLO E, GALIMBERTI S, PETRINI M (2008).
Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular
lymphoma. HEMATOLOGICAL ONCOLOGY, vol. 26, p. 179-181, ISSN: 0278-0232
4
2008
0
4
2008
1
4
2008
2
GALIMBERTI S, CANESTARO M, CIANCIA E, FAZZI R, MARASCA R, PETRINI M
(2008). Bortezomib is able to reduce angiogenesis in half of patients affected by
idiopathic myelofibrosis: an ex vivo study. LEUKEMIA RESEARCH, vol. 32, p. 13241325, ISSN: 0145-2126
Buda G, Orciuolo E, Galimberti S, Benedetti E, Caracciolo F, Cervetti G, Carulli G,
Papineschi F, Petrini M. (2008). Complex translocation t(3;9;22)(q21;q34;q11) at
diagnosis is a negative prognostic index in chronic myeloid leukemia. . LEUKEMIA
RESEARCH, vol. 32, p. 192-194, ISSN: 0145-2126
Orciuolo E, Buda G, Galimberti S, Cervetti G, Cecconi N, Papineschi F, Petrini M.
(2008). Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy
resistance index in chronic myeloid leukaemia. . LEUKEMIA RESEARCH, vol. 32, p.
190-191, ISSN: 0145-2126
4
2008
3
Orciuolo E, Buda G, Galimberti S, Cecconi N, Cervetti G, Petrini M. (2008).
Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. .
LEUKEMIA RESEARCH, vol. 32, p. 188-190, ISSN: 0145-2126
4
2008
4
FOCOSI D, KAST RE, GALIMBERTI S, PETRINI M (2008). Conditioning response to
granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine
deaminase complex. JOURNAL OF LEUKOCYTE BIOLOGY, vol. 84, p. 331-337,
ISSN: 0741-5400
4
2008
5
4
2008
6
4
2008
7
4
2008
8
4
2008
9
5
2008
0
5
2008
1
5
2008
2
5
2008
3
5
2008
4
Focosi D, Caracciolo F, Galimberti S, Papineschi F, Petrini M. (2008). False positive
PET scanning caused by inactivated influenza virus vaccination during complete
remission from anaplastic T-cell lymphoma. . ANNALS OF HEMATOLOGY, vol. 87, p.
343-344, ISSN: 0939-5555
Mattii L, Battolla B, D'Alessandro D, Trombi L, Pacini S, Cascone MG, Lazzeri L,
Bernardini N, Dolfi A, Galimberti S, Petrini M. Source (2008). Gelatin/PLLA sponge-like
scaffolds allow proliferation and osteogenic differentiation of human mesenchymal
stromal cells. . MACROMOLECULAR BIOSCIENCE, vol. 8, p. 819-826, ISSN: 16165187
TROMBI L, D'ALESSANDRO D, PACINI S, FIORENTINO B, SCARPELLINI M, FAZZI
R, GALIMBERTI S, GUAZZINI S, PETRINI M (2008). Good manufacturing practicegrade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and
supports in vitro osteogenic differentiation. TRANSFUSION, vol. 48, p. 2246-2251,
ISSN: 0041-1132
CANNIZZO E, CARULLI G, AZZARÀ A, GALIMBERTI S, ZUCCA A, PETRINI M
(2008). JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?. LEUKEMIA
RESEARCH, vol. 32, p. 1636-1637, ISSN: 0145-2126
MAGGINI V, BUDA G, GALIMBERTI S, MARTINO A, ORCIUOLO E, MORABITO F,
BONO R, BARALE R, PETRINI M, ROSSI AM (2008). Lack of association of NQO1
and GSTP1 polymorphisms with multiple myeloma risk. LEUKEMIA RESEARCH, vol.
32, p. 988-990, ISSN: 0145-2126
Focosi D, Caracciolo F, Galimberti S, Papineschi F, Petrini M. (2008). Long-term
propylthiouracil use and acute myeloid leukemia: a case report and review of the
literature. . ANNALS OF HEMATOLOGY, vol. 87, p. 233-235, ISSN: 0939-5555
MAGGINI V, BUDA G, MARTINO A, PRESCIUTTINI S, GALIMBERTI S, ORCIUOLO
E, BARALE R, PETRINI M, ROSSI AM (2008). MDR1 diplotypes as prognostic
markers in multiple myeloma. PHARMACOGENETICS AND GENOMICS, vol. 18, p.
383-389, ISSN: 1744-6872
BUDA G, ORCIUOLO E, MAGGINI V, GALIMBERTI S, BARALE R, ROSSI AM,
PETRINI M (2008). MDR1 modulates apoptosis in CD34+ leukemic cells. ANNALS OF
HEMATOLOGY, vol. 87, p. 1017-1018, ISSN: 0939-5555
BUDA G, ORCIUOLO E, MAGGINI V, GALIMBERTI S, BARALE R, ROSSI AM,
PETRINI M (2008). Other mechanisms to explain the role of reduced folate carrier in
cancer. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 80, p. 365-366, ISSN: 09024441
GALIMBERTI S, CANESTRARO M, PACINI S, FAZZI R, ORCIUOLO E, TROMBI L,
MATTII L, BATTOLLA B, CAPODANNO A, COLLECCHI P, VERONI F, SIMI P,
PIAGGI S, CASINI A, PETRINI M. LEUK RES (2008). PS-341 (Bortezomib) inhibits
proliferation and induces apoptosis of megakaryoblastic MO7-e cells. LEUKEMIA
RESEARCH, vol. 32, p. 103-112, ISSN: 0145-2126
5
2008
5
5
2008
6
5
2008
7
5
2008
8
5
2008
9
6
2008
0
6
2008
1
6
2008
2
6
2008
3
6
2008
4
6
2007
5
allegati
FOCOSI D, BENEDETTI E, MAGGI F, PAPINESCHI F, GALIMBERTI S,
CECCHERINI-NELLI L, PETRINI M (2008). Preemptive valganciclovir for
cytomegalovirus infection in hematological patients. TRANSPLANT INFECTIOUS
DISEASE, vol. 10, p. 375-376, ISSN: 1398-2273
Pelosini M, Focosi D, Rita F, Galimberti S, Caracciolo F, Benedetti E, Papineschi F,
Petrini M. (2008). Progressive multifocal leukoencephalopathy: report of three cases in
HIV-negative hematological patients and review of literature. . ANNALS OF
HEMATOLOGY, vol. 87, p. 405-412, ISSN: 0939-5555
Cervetti G, Carulli G, Galimberti S, Azzarà A, Cannizzo E, Buda G, Orciuolo E, Petrini
M (2008). Reduction of immunoglobulin levels during imatinib therapy of chronic
myeloid leukemia. . LEUKEMIA RESEARCH, vol. 32, p. 191-192, ISSN: 0145-2126
MAGGINI VALENTINA, BUDA GABRIELE, GALIMBERTI S, CONIDI ELENA,
GIULIANI NICOLA, MORABITO FORTUNATO, GENESTRETI GIOVENZIO,
JACOPINO PASQUALE, RIZZOLI VITTORIO, BARALE ROBERTO, PETRINI MARIO,
ROSSI ANNA MARIA (2008). Response to chemotherapy and tandem autologous
transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.
LEUKEMIA RESEARCH, vol. 32, p. 49-53, ISSN: 0145-2126
CERVETTI G, GALIMBERTI S, ANDREAZZOLI F, FAZZI R, CECCONI N,
CARACCIOLO F, PETRINI M (2008). Rituximab as treatment for minimal residual
disease in hairy cell leukaemia: extended follow-up. BRITISH JOURNAL OF
HAEMATOLOGY, vol. 143, p. 296-298, ISSN: 0007-1048
Mattii L, Battolla B, Moscato S, Fazzi R, Galimberti S, Bernardini N, Dolfi A, Petrini M.
(2008). The small peptide OGP(10-14) acts through Src kinases and RhoA pathways in
Mo-7e cells: morphologic and immunologic evaluation. . MEDICAL SCIENCE
MONITOR, vol. 14, p. BR103-BR108, ISSN: 1234-1010
Cervetti G, Carulli G, Galimberti S, Azzarà A, Buda G, Orciuolo E, Pelosini M, Petrini M
(2008). Transitory marrow aplasia during Imatinib therapy in a patient with chronic
myeloid leukemia.. LEUKEMIA RESEARCH, vol. 32, p. 194-195, ISSN: 0145-2126
Benedetti E, Lippolis PV, Caracciolo F, Galimberti S, Papineschi F, Pelosini M, Focosi
D, Stella SM, Neri E, Seccia M, Petrini M (2008). Ultrasound findings guided a
successful hemicolectomy in a leukemic patient with neutropenic enterocolitis .
JOURNAL OF ULTRASOUND, vol. 11, p. 97-101, ISSN: 1971-3495
Buda G, Orciuolo E, Galimberti S, Petrini M, Maggini V, Barale R, Rossi AM. (2008).
Unusual association of endometrial cancer and multiple myeloma. . GYNECOLOGIC
ONCOLOGY, vol. 110, p. 265-266, ISSN: 0090-8258
GALIMBERTI S, CANESTRARO M, KHAN R, BUDA G, ORCIUOLO E, GUERRINI F,
FAZZI R, MAFFEI R, MARASCA R, PETRINI M. LEUKEMIA. AUG I.F (2008).
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39
cell lines. LEUKEMIA, vol. 22, p. 628-631, ISSN: 0887-6924
Orciuolo E, Buda G, Cecconi N, Galimberti S, Petrini M. (2007). A therapy resistant
myelodysplastic syndrome characterized by the presence of the rare reciprocal
translocation t(3;12)(q26.2;p13).. LEUKEMIA RESEARCH, vol. 31, p. 1599-1600,
ISSN: 0145-2126
6
2007
6
Orciuolo E, Buda G, Galimberti S, Sordi E, Cervetti G, Petrini M. (2007). Concomitant
appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a
patient with chronic myeloid leukemia in chronic phase: an alarm for changing
therapeutic strategy.. CANCER GENETICS AND CYTOGENETICS, vol. 177, p. 166167, ISSN: 0165-4608
6
2007
7
Pelosini M, Galimberti S, Benedetti E, Caracciolo F, Fazzi R, Petrini M, Papineschi F.
(2007). Skin and stomach graft versus host disease after syngeneic BMT in CML: a
case report.. LEUKEMIA RESEARCH, vol. 31, p. 1603-1604, ISSN: 0145-2126
6
2007
8
Buda G, Orciuolo E, Galimberti S, Carulli G, Petrini M. Source (2007). Association of
PIM gene translocation and TEL/AML1 rearrangement. LEUKEMIA RESEARCH, vol.
31, p. 1761-1762, ISSN: 0145-2126
6
2007
9
7
2007
0
7
2007
1
7
2007
2
7
2007
3
7
2007
4
7
2007
5
7
2007
6
Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G,
Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM (2007). Association of folate
transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after
chemotherapy and tandem autologous transplantation.. LEUKEMIA, vol. 21, p. 176178, ISSN: 0887-6924
BUDA G, GALIMBERTI S, SCARPATO R, CARACCIOLO F, CARULLI G, MAGGINI V,
BARALE R, PETRINI M. (2007). Atypical APL including multiple translocations and
abnormal response to micronuclei induction test. EUROPEAN JOURNAL OF
CLINICAL INVESTIGATION, vol. 37, p. 155-156, ISSN: 0014-2972
Orciuolo E, Galimberti S, Petrini M. (2007). Bortezomib inhibits T-cell function versus
infective antigenic stimuli in a dose-dependent manner in vitro. LEUKEMIA
RESEARCH, vol. 31, p. 1026-1027, ISSN: 0145-2126
Galimberti S, Ciabatti E, Ottimo F, Rossi A, Trombi L, Carulli G, Cervetti G, Matti L,
Bianchi G, Petrini M. (2007). Cell clonality in hypereosinophilic syndrome: what
pathogenetic role?. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol. 25, p.
17-22, ISSN: 0392-856X
ABRUZZESE E, GOZZETTI A, GALIMBERTI S, TRAWINSKA MM, CARAVITA T,
SINISCALCHI A, CERVETTI G, MAURIELLO A, COLETTA AM, DE FABRITIIS P
(2007). Characterization of Ph-negative abnormal clones emerging during imatinib
therapy. CANCER, vol. 109, p. 2466-2472, ISSN: 0008-543X
ORCIUOLO E, STANZANI M, CANESTRARO M, GALIMBERTI S, CARULLI G, LEWIS
R, PETRINI M, KOMANDURI KV (2007). Effects of Aspergillus fumigatus gliotoxin and
methylprednisolone on human neutrophils: implications for the pathogenesis of
invasive aspergillosis. JOURNAL OF LEUKOCYTE BIOLOGY, vol. 82, p. 839-848,
ISSN: 0741-5400
GALIMBERTI S, NAGY B, BENEDETTI E, PACINI S, BRIZZI S, CARACCIOLO F,
PAPINESCHI F, CIABATTI E, GUERRINI F, FAZZI R, CANESTRARO M, PETRINI M
(2007). Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene
expression in patients affected by aggressive mantle cell lymphoma treated by the RHyper-CVAD regimen. Leuk Lymphoma. LEUKEMIA & LYMPHOMA, vol. 48, p. 15021509, ISSN: 1042-8194
BUDA G, MAGGINI V, GALIMBERTI S, BARALE R, ROSSI AM, PETRINI M. LEUK
RES (2007). Folate levels and methylation of CDKI proteins. LEUKEMIA RESEARCH,
vol. 31, p. 569-570, ISSN: 0145-2126
7
2007
7
7
2007
8
7
2007
9
8
2007
0
BUDA G, MAGGINI V, GALIMBERTI S, BARALE R, ROSSI AM, PETRINI M (2007).
Folate levels in cancer: a vitamin for a new challenge. ANNALS OF HEMATOLOGY,
vol. 86, p. 389, ISSN: 0939-5555
BUDA G, MAGGINI V, GALIMBERTI S, MARTINO A, GIULIANI N, MORABITO F,
GENESTRETI G, IACOPINO P, RIZZOLI V, BARALE R, ROSSI AM, PETRINI M. JUN,
-. I.F (2007). MDR1 polymorphism influences the outcome of multiple myeloma
patients. BRITISH JOURNAL OF HAEMATOLOGY, vol. 137, p. 454-456, ISSN: 00071048
Orciuolo E, Cecconi N, Galimberti S, Papineschi F, Petrini M (2007). Match unrelated
bone marrow transplantation in a case of high risk myelodysplastic syndrome treated
with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating
agent. . LEUKEMIA RESEARCH, vol. 31, p. 1321-1323, ISSN: 0145-2126
GUERRINI F, GALIMBERTI S, CIABATTI E, BRIZZI S, TESTI R, POLLASTRINI A,
FALINI B, PETRINI M (2007). Molecular detection of GNNK- and GNNK+ c-kit
isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. LEUKEMIA,
vol. 21, p. 2056-2058, ISSN: 0887-6924
8
2007
1
BUDA G, MAGGINI V, GALIMBERTI S, BARALE R, ROSSI AM, PETRINI M (2007).
NQO1*2 polymorphism and response to treatment in patients with multiple myeloma.
LEUKEMIA RESEARCH, vol. 31, p. 1029-1030, ISSN: 0145-2126
8
2007
2
FAZZI R, ORCIUOLO E, TROMBI L, MATTII L, BATTOLA B, RICCIONI R, CARULLI
G, GALIMBERTI S, PETRINI M (2007). PEG-Filgrastim activity on granulocyte
functions. LEUKEMIA RESEARCH, vol. 31, p. 1453-1455, ISSN: 0145-2126
8
2007
3
8
2007
4
8
2007
5
8
2007
6
8
2007
7
82007
Buda G, Orciuolo E, Cecconi N, Galimberti S, Cervetti G, Petrini M. (2007). Poor
prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation,
t(9;10;22) (q34;q24;q11). LEUKEMIA RESEARCH, vol. 31, p. 1765-1766, ISSN: 01452126
NAGY B, GALIMBERTI S, BENEDETTI E, CARACCIOLO F, PACINI S, VILPO J,
FERRER A, ELONEN E, FRANSSILA K, KNUUTILA S, PETRINI M (2007). RAF-1
over-expression does condition survival of patients affected by aggressive mantle cell
lymphoma. LEUKEMIA RESEARCH, vol. 31, p. 1595-1597, ISSN: 0145-2126
Buda G, Galimberti S, Orciuolo E, Caracciolo F, Cecconi N, Gasparini M, Petrini M.
(2007). Stable low IgG levels in relapsed non-Hodgkin's lymphomas. . ANNALS OF
HEMATOLOGY, vol. 86, p. 851-853, ISSN: 0939-5555
Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, Carlucci F, Petrini M.
(2007). Suspension of bone marrow-derived undifferentiated mesenchymal stromal
cells for repair of superficial digital flexor tendon in race horses. . TISSUE
ENGINEERING, vol. 13, p. 2949-2955, ISSN: 1076-3279
GALIMBERTI S, PALUMBO GA, CARACCIOLO F, BENEDETTI E, PELOSINI M,
BRIZZI S, CIABATTI E, FAZZI R, STELITANO C, QUINTANA G, CONTE E, TIBULLO
D, DI RAIMONDO F, PETRINI M (2007). The efficacy of rituximab plus Hyper-CVAD
regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa
polymorphisms. JOURNAL OF CHEMOTHERAPY, vol. 19, p. 315-321, ISSN: 1120009X
Buda G, Carulli G, Orciuolo E, Cannizzo E, Zucca A, Azzarà A, Rossi A, Galimberti S,
8
8
2006
9
9
2006
0
9
2006
1
9
2006
2
9
2006
3
9
2006
4
9
2005
5
9
2005
6
9
2005
7
9
2005
8
Cecconi N, Petrini M. (2007). Two cases of plasma cell leukemia with atypical
immunophenotype. ACTA HAEMATOLOGICA, vol. 118, p. 27-29, ISSN: 0001-5792
CARULLI G, MATTII L, AZZARA A, BRIZZI S, GALIMBERTI S, ZUCCA A,
BENEDETTI E, PETRINI M (2006). Actin polymerization in neutrophils from donors of
peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated
recombinant human granulocyte colony-stimulating factor. AMERICAN JOURNAL OF
HEMATOLOGY, vol. 81, p. 318-323, ISSN: 0361-8609
Orciuolo E, Fazzi R, Galimberti S, Testi C, Azzara' A, Carulli G, Petrini M. (2006).
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient:
difficulties at diagnosis and rational of the therapeutic strategy.. LEUKEMIA
RESEARCH, vol. 30, p. 349-353, ISSN: 0145-2126
BOLLI N, GALIMBERTI S, MARTELLI MP, TABARRINI A, ROTI G, MECUCCI C,
MARTELLI MF, PETRINI M, FALINI B (2006). Cytoplasmic nucleophosmin in myeloid
sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. LANCET
ONCOLOGY, vol. 7, p. 350-352, ISSN: 1470-2045
GALIMBERTI S, BENEDETTI E, MORABITO F, PETRINI I, BATTOLLA B,
PAPINESCHI F, FAZZI R, CIABATTI E, MARTINO M, CUZZOLA M, CONSOLE G,
IACOPINO P, PETRINI M (2006). Different gamma/delta T clones sustain GVM and
GVH effects in multiple myeloma patients after non-myeloablative transplantation.
LEUKEMIA RESEARCH, vol. 30, p. 529-535, ISSN: 0145-2126
PELOSINI M, BENEDETTI E, GALIMBERTI S, CARACCIOLO F, PETRINI M, FAZZI R,
ANDREAZZOLI F, PAPINESCHI F (2006). Granulocytic sarcoma and subsequent
acute leukemia recurrence with different biologic characteristics 5 years after
allogeneic bone marrow transplantation for acute myeloid leukemia. BONE MARROW
TRANSPLANTATION, vol. 37, p. 897-898, ISSN: 0268-3369
BUDA G, ROMAGNOLI MC, GALIMBERTI S, FIGUS M, PAPINESCHI F, NARDI M,
PETRINI M (2006). Simultaneous appearance of acute myeloid leukemia in a patient
with bilateral primary uveal melanoma. MELANOMA RESEARCH, vol. 16, p. 467-468,
ISSN: 0960-8931
Carulli G, Canigiani S, Volpini M, Ciancia EM, Galimberti S, Zucca A, Marini A, Buda G,
Petrini M (2005). Bone marrow infiltration in B-cell non-Hodgkin's lymphomas:
comparison between flow cytometry and bone marrow biopsy.. RECENTI PROGRESSI
IN MEDICINA, vol. 96, p. 284-290, ISSN: 0034-1193
GALIMBERTI S, BENEDETTI E, MORABITO F, FAZZI R, PACINI S, ANDREAZZOLI
F, MARTINO M, IACOPINO P, PETRINI M (2005). Chimerism does not influence graftversus-myeloma and graft-versus-host disease in reduced intensity setting.
TRANSPLANT IMMUNOLOGY, vol. 15, p. 173-177, ISSN: 0966-3274
Mattii L, Azzarà A, Fazzi R, Carulli G, Chimenti M, Cecconi N, Galimberti S, Petrini M.
(2005). Glycosylated or non-glycosylated G-CSF differently influence human
granulocyte functions through RhoA. . LEUKEMIA RESEARCH, vol. 29, p. 1285-1292,
ISSN: 0145-2126
Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M. (2005). High
efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated
with systemic autoimmune diseases.. CLINICAL AND EXPERIMENTAL
RHEUMATOLOGY, vol. 23, p. 877-880, ISSN: 0392-856X
9
2005
9
1
02005
0
Cervetti G, Galimberti S, Carulli G, Petrini M. (2005). Imatinib therapy in
Hypereosinophilic Syndrome: a case of molecular remission.. LEUKEMIA RESEARCH,
vol. 29, p. 1097-1098, ISSN: 0145-2126
Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C,
Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M.
(2005). Prognostic role of minimal residual disease in multiple myeloma patients after
non-myeloablative allogeneic transplantation.. LEUKEMIA RESEARCH, vol. 29, p. 961966, ISSN: 0145-2126
1
02005
1
Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M
(2005). Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in
patients with chronic myeloid leukemia during Imatinib treatment. CANCER GENETICS
AND CYTOGENETICS, vol. 162, p. 57-62, ISSN: 0165-4608
1
02004
2
Papineschi F, Benedetti E, Galimberti S, Caracciolo F, Fazzi R, Petrini M. (2004). A
myeloablative allograft after rejection of two consecutive nonmyeloablative transplants
from two different HLA identical siblings.. BONE MARROW TRANSPLANTATION, vol.
33, p. 659-660, ISSN: 0268-3369
1
02004
3
Cervetti G, Galimberti S, Fazzi R, Papineschi F, Azzarà A, Simi P, Petrini M. (2004).
Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients
treated with Imatinib.. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 34,
p. 243-244, ISSN: 0014-2972
1
02004
4
Fazzi R, Galimberti S, Pacini S, Testi R, Azzarà A, Orciuolo E, Trombi L, Metelli MR,
Petrini M (2004). Bone and bone marrow interactions: hematological activity of
osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on
human megakaryocytopoiesis: focus on essential thrombocythemia. . LEUKEMIA
RESEARCH, vol. 28, p. 1097-1105, ISSN: 0145-2126
1
02004
5
Mattii L, Fazzi R, Moscato S, Segnani C, Pacini S, Galimberti S, D'Alessandro D,
Bernardini N, Petrini M. (2004). Carboxy-terminal fragment of osteogenic growth
peptide regulates myeloid differentiation through RhoA.. JOURNAL OF CELLULAR
BIOCHEMISTRY. SUPPLEMENT, vol. 93, p. 1231-1241, ISSN: 0733-1959
1
02004
6
Orciuolo E, Azzarà A, Bandini G, Galimberti S, Bonifazi F, Fazzi R, Petrini M (2004).
Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation,
of myelodysplastic syndrome in the patient and the donor.. BONE MARROW
TRANSPLANTATION, vol. 33, p. 859-861, ISSN: 0268-3369
1
02004
7
Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V,
Petrini M (2004). Evaluation of BCRP and MDR-1 co-expression by quantitative
molecular assessment in AML patients.. LEUKEMIA RESEARCH, vol. 28, p. 367-372,
ISSN: 0145-2126
1
02004
8
1
02004
9
12004
Galimberti S, Cervetti G, Cecconi N, Fazzi R, Pacini S, Guerrini F, Manetti C,
Caracciolo F, Petrini M. (2004). Quantitative molecular evaluation of minimal residual
disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by
alemtuzumab (Campath-1H).. JOURNAL OF IMMUNOTHERAPY, vol. 27, p. 389-393,
ISSN: 1524-9557
Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M.
(2004). Rituximab as treatment for minimal residual disease in hairy cell leukaemia. .
EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 73, p. 412-417, ISSN: 0902-4441
Cervetti G, Galimberti S, Cecconi N, Caracciolo F, Petrini M. (2004). Role of low-dose
1
0
1
12004
1
2-CdA in refractory or resistant lymphoplasmocytic lymphoma.. JOURNAL OF
CHEMOTHERAPY, vol. 16, p. 388-391, ISSN: 1120-009X
Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, Petrini M.
(2004). Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia
patients at diagnosis. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 42, p. 45-51,
ISSN: 0902-4441
1
12003
2
allegati
Gozzini A, Rovida E, Dello Sbarba P, Galimberti S, Santini V. (2003). Butyrates, as a
single drug, induce histone acetylation and granulocytic maturation: possible selectivity
on core binding factor-acute myeloid leukemia blasts.. CANCER RESEARCH, vol. 63,
p. 8955-8961, ISSN: 0008-5472
1
12003
3
Fazzi R, Pacini S, Testi R, Azzarà A, Galimberti S, Testi C, Trombi L, Metelli MR,
Petrini M. (2003). Carboxy-terminal fragment of osteogenic growth peptide in vitro
increases bone marrow cell density in idiopathic myelofibrosis. . BRITISH JOURNAL
OF HAEMATOLOGY, vol. 121, p. 76-85, ISSN: 0007-1048
1
12003
4
1
12003
5
1
12003
6
1
12003
7
1
12003
8
1
12003
9
1
22003
0
1
2003
2
PARDINI C, VAGLINI F, GALIMBERTI S, CORSINI GU (2003). Dose-dependent
induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture.
NEUROPHARMACOLOGY, vol. 45, p. 182-189, ISSN: 0028-3908
FAZZI R, CARACCIOLO F, GALIMBERTI S, PETRINI M (2003). Early reappearance of
primary solid cancer in patients treated with purine analogs. JOURNAL OF
CHEMOTHERAPY, vol. 15, p. 406-408, ISSN: 1120-009X
GALIMBERTI S, ROSSI A, PALUMBO GA, MORABITO F, GUERRINI F, VINCELLI I,
FAZZI R, SANTINI V, PETRINI M (2003). FLT3 mutations do not influence MDR-1
gene expression in acute myeloid leukemia. ANTICANCER RESEARCH, vol. 23, p.
3419-3426, ISSN: 0250-7005
Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M (2003). Low dose 2-CdA
schedule activity in splenic marginal zone lymphomas.. HEMATOLOGICAL
ONCOLOGY, vol. 21, p. 163-168, ISSN: 0278-0232
NAGY B, FERRER A, LARRAMENDY ML, GALIMBERTI S, AALTO Y, CASAS S,
VILPO J, RUUTU T, VETTENRANTA K, FRANSSILA K, KNUUTILA S (2003).
Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small
lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain
reaction analysis. HAEMATOLOGICA, vol. 88, p. 654-658, ISSN: 0390-6078
GALIMBERTI S, MORABITO F, GUERRINI F, PALUMBO GA, AZZARA A, MARTINO
M, BENEDETTI E, DI RAIMONDO F, PETRINI M (2003). Peripheral blood stem cell
contamination evaluated by a highly sensitive molecular method fails to predict
outcome of autotransplanted multiple myeloma patients. BRITISH JOURNAL OF
HAEMATOLOGY, vol. 120, p. 405-412, ISSN: 0007-1048
GALIMBERTI S, GUERRINI F, MORABITO F, PALUMBO GA, DI RAIMONDO F,
PAPINESCHI F, CARACCIOLO F, FAZZI R, CERVETTI G, CUZZOCREA A, PETRINI
M (2003). Quantitative molecular evaluation in autotransplant programs for follicular
lymphoma: efficacy of in vivo purging by Rituximab. BONE MARROW
TRANSPLANTATION, vol. 32, p. 57-63, ISSN: 0268-3369
GALIMBERTI S, TESTI R, GUERRINI F, FAZZI R, PETRINI M (2003). The clinical
relevance of the expression of several multidrug-resistant-related genes in patients with
1
1
22002
2
1
22002
3
1
22002
4
1
22002
5
1
22001
6
1
22001
7
1
21999
8
primary acute myeloid leukemia. JOURNAL OF CHEMOTHERAPY, vol. 15, p. 374379, ISSN: 1120-009X
FAZZI R, GALIMBERTI S, TESTI R, PACINI S, TRASCIATTI S, ROSINI S, PETRINI M
(2002). Bone and bone marrow interactions: hematological activity of osteoblastic
growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human
hematopoietic stem cells. LEUKEMIA RESEARCH, vol. 26, p. 839-848, ISSN: 01452126
Fazzi R, Testi R, Trasciatti S, Galimberti S, Rosini S, Piras F, L'Abbate G, Conte A,
Petrini M. (2002). Bone and bone-marrow interactions: haematological activity of
osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing
properties on white blood cells and peripheral blood stem cells in mice. . LEUKEMIA
RESEARCH, vol. 26, p. 19-27, ISSN: 0145-2126
Riccioni R, Galimberti S, Cervetti G, Fazzi R, Caracciolo F, Petrini M (2002). Oral
cyclophosphamide therapy for patients with residual or relapsed indolent-type
lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients
with apparent transformed indolent lymphoma.. LEUKEMIA & LYMPHOMA, vol. 43, p.
1803-1806, ISSN: 1042-8194
GALIMBERTI S, MARASCA R, CARACCIOLO F, FAZZI R, PAPINESCHI F,
BENEDETTI E, GUERRINI F, MORABITO F, OLIVA E, DI RENZO N, FEDERICO M,
PETRINI M, TORELLI G, FOR GISL (2002). The role of molecular monitoring in
autotransplantation
for
non-Hodgkin's
lymphoma.
BONE
MARROW
TRANSPLANTATION, vol. 29, p. 581-587, ISSN: 0268-3369
Ceretelli S, Petrini M, Galimberti S, Testi C, Frizzera G. (2001). Interferon-alpha activity
in a case of severe autoimmune lymphoproliferative disease.. ANNALS OF
HEMATOLOGY, vol. 80, p. 49-52, ISSN: 0939-5555
GALIMBERTI S, RICCIONI R, AZZARA A, TESTI R, FAZZI R, TESTI C, PETRINI M
(2001). Unusual morphology in a case of large granular cell leukemia. ANNALS OF
HEMATOLOGY, vol. 80, p. 755-757, ISSN: 0939-5555
Galimberti S, Brizzi F, Mameli M, Petrini M. (1999). An advantageous method to
evaluate IgH rearrangement and its role in minimal residual disease detection..
LEUKEMIA RESEARCH, vol. 23, p. 921-929, ISSN: 0145-2126
1
21999
9
Galimberti S, Papineschi F, Carmignani A, Testi R, Fazzi R, Petrini M. (1999). Arsenic
and all-trans retinoic acid as induction therapy before autograft in a case of relapsed
resistant
secondary
acute
promyelocytic
leukemia..
BONE
MARROW
TRANSPLANTATION, vol. 24, p. 345-348, ISSN: 0268-3369
1
31999
0
Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini
M, Torelli G. (1999). Missense mutations in the PML/RARalpha ligand binding domain
in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. .
HAEMATOLOGICA, vol. 84, p. 963-968, ISSN: 0390-6078
1
31998
1
1
31997
2
1 997
Galimberti S, Marchetti A, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G, Petrini M.
(1998). Multidrug resistance related genes and p53 expression in human non small cell
lung cancer.. ANTICANCER RESEARCH, vol. 18, p. 2973-2979, ISSN: 0250-7005
Petrini M, Galimberti S (1997). 124. Treatment of multidrug resistance in oncology and
hematology. . TUMORI, vol. 83, p. s17-s20, ISSN: 0300-8916
Di Simone D, Galimberti S, Basolo F, Ciardiello F, Petrini M, Scheper RJ. (1997). c-Ha-
3
3
ras transfection and expression of MDR-related genes in MCF-10A human breast cell
line. . ANTICANCER RESEARCH, vol. 17, p. 3587-3592, ISSN: 0250-7005
1
31997
4
Di Simone D, Galimberti S, Mattii L, Petrini M. (1997). c-Jun and GST-pi expression in
human plasma cells. . HAEMATOLOGICA, vol. 82, p. 69-70, ISSN: 0390-6078
1
31995
5
Petrini M, Galimberti S, Sabbatini A, Bianchi F, Bernardini N, Dolfi A, Lupetti M. (1995).
Expression of multidrug resistance (mdr) gene(s) in primary lymphoid organs of
chicken immune system during embryonic development. . EXPERIENTIA, vol. 51, p.
137-140, ISSN: 0014-4754
1
31993
6
Pasquinelli P, Petrini M, Mattii L, Galimberti S, Saviozzi M, Malvaldi G. (1993).
Biological effects of PEMF (pulsing electromagnetic field): an attempt to modify cell
resistance to anticancer agents. . JOURNAL OF ENVIRONMENTAL PATHOLOGY
TOXICOLOGY AND ONCOLOGY, vol. 12, p. 193-197, ISSN: 0731-8898
1
31993
7
Galimberti S, Bianchi F, Bernardini N, Mattii L, Dolfi A, Lupetti M, Petrini M. (1993).
Scanning electron microscopy of multidrug resistant cells in haematological and
mammary malignancies. . CELLULAR AND MOLECULAR BIOLOGY, vol. 39, p. 543551, ISSN: 0145-5680
Si autorizza la pubblicazione del presente Curriculum Vitae
Pisa, Ottobre 2014
Sara Galimberti